Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ferring Pharmaceuticals and Karolinska Institutet announce new alliance

Ferring Pharmaceuticals and Karolinska Institutet announce new alliance

27th January 2016

Ferring Pharmaceuticals has announced a new collaboration with the Karolinska Institutet focusing on the study of the human microbiome.

An agreement has been signed for the establishment of a research centre exploiting the human microbiome, with the programme to be fully funded by Ferring and governed by a joint steering committee.

Leveraging the experience of both organisations, the research will partly be carried out at the Science for Life Laboratory, offering access to a broad technical platform for studying complex microbiological communities in well-defined human material.

Professor Lars Engstrand of the Karolinska Institutet has been selected to lead the new research programme as its director.

Dr Per Falk, executive vice-president and chief scientific officer at Ferring, said: "This collaboration with Karolinska Institutet involving SciLifeLab will help to understand the role of the microflora in our key therapy areas and develop innovative treatments to better serve the needs of our patients."

This comes after the firm recently agreed a deal with Cosmo Pharmaceuticals that will see Ferring gain the rights to the ulcerative colitis therapy Cortiment MMX in Japan.ADNFCR-8000103-ID-801811091-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.